Introduction:
In 2021 a Spanish group developed the FEOS score(FS), which reflects the improved in patients treated with MA, using: Forced expiratory volume in the first minute (FEV1), Exacerbations, dose of chronic Oral corticosteroids and Symptoms measured by the ACT scale.
Material and methods:
Observational study with a cohort of 33 patients who started treatment with Reslizumab between February 2018 and February 2022 in a tertiary level hospital with prospective follow-up at one, two and three years after.
Results:
91.9% were women, with a median age of 50 years (IQR 42-65). 10 patients had already received a previous MA, discontinued in 7 due to treatment failure, in two for allergic reaction and one for adverse event. 9 patients suffered anosmia, 8 of them recovered their sense of smell at follow-up. 2
During first year of follow-up, 18 patients continued with treatment. It was necessary to suspend it due to lack of improvement in three patients. A statistically significant difference of 19.9 was evidenced in the FS in favor of the first group (p=0.030). with a mean of 72.56 (DE 2.74)in those who continued treatment while those who discontinued had 52.67 (SD 14.93).
The FSŽs mean at one year was 69.71 (SD 15), at two years the median was 74 (IQR 20-76) and at 3 years the mean was 86.67 (SD 12).
SŽs means were compared at all three reviews depending on previous MA treatment, showing differences in favor of the group without previous MA treatment, although this was only statistically significant at the 3-year follow-up.

Conclusion

The FS reflects the improvement of patients with severe eosinophilic asthma treated with MA